The shift from dose-intense standard chemotherapy to therapies targeting specific signaling pathways, molecular targets, or elements of the tumor microenvironment presents a number of challenges to the oncology professional and the patient. Cancer diagnosis and treatment requires precision in the diagnostic evaluation (asking all the critical diagnostic questions at the [ Read More ]
Sandra Kurtin, RN, MS, AOCN, ANP-C
Ms Kurtin is a nurse practitioner at the University of Arizona Cancer Center and a clinical assistant professor of medicine at the University of Arizona colleges of medicine and nursing. Her practice focuses on patients with hematologic and gastrointestinal malignancies and those participating in phase 1 clinical trials. She serves as an educator for oncology fellows, residents, nurses and nursing students, and she has mentored many in research, evidence-based practice, and publishing. She also teaches regionally, nationally, and internationally at conferences. She serves on a number of international boards including the Myelodysplastic Syndromes Foundation and the International Myeloma Foundation.